Replies to post #3063 on Jaguar Health Inc (JAGX)

[powerbattles]

Additionally, Jaguar is supporting investigator-initiated studies of crofelemer for rare disease indications like microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in various regions, with results anticipated by the end of 2023 and 2024.